Last updated: September 18, 2023
Sponsor: Xi'an International Medical Center Hospital
Overall Status: Completed
Phase
N/A
Condition
Covid-19
Pneumonia
Treatment
Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose
Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment
Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C
Clinical Study ID
NCT04664010
XianInternationalMCH_HXJ
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with mild and severe COVID-19 confirmed according to the Diagnosis andTreatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7) that was issuedby the National Health Commission & State Administration of Traditional ChineseMedicine;
- Patients with suspected COVID-19 who meet one of the following pathogenic orserological evidence are also confirmed infected with the virus: a) COVID-19 nucleicacid test positive, as confirmed by real-time fluorescence RT-PCR detection; b) viralgene sequencing is highly homologous with the known COVID-19; c) serum test positivefor both COVID-19 specific IgM and IgG antibodies; d) serum IgG antibody turnspositive from negative or IgG antibody level in the recovering phase rises four timesor higher than in the acute phase
- Patients with moderate COVID-19 have fever and respiratory symptoms and present withthe imaging features of coronavirus disease
- Subjects will be considered developing severe COVID-19 if one of the followingconditions occur: a) dyspnea, respiratory ≥ 30 beats/minute, blood oxygen saturation ≤ 93%, partial pressure of arterial oxygen (PaO2)/ fraction of inspired oxygen ratio (FiO2) ≤ 300, and /or lung infiltrates > 50% within 24 to 48 hours
- Age > 18 years, of either sex Provision of written informed consent
Exclusion
Exclusion Criteria:
- Patients with critical COVID-19 presenting with shock, acute respiratory distresssyndrome, multiple organ failure
- Patients with mild COVID-19
- Pregnant or lactating woman
- Upon the investigator's judgment, patients had the diseases that possibly influencepatient participation in this study or study outcomes (such as malignant disease,autoimmune disease, severe malnutrition, liver and kidney disease, blood disease,nervous system disease, endocrine diseases) or currently suffer from the diseases thatseriously affect the immune system (such as human immunodeficiency virus infection) orblood system, or splenectomy/organ transplantation.
- Upon the request of the investigators or sponsors, patients with other acute malignantor chronic disease or mental disorder are not suitable for participation in thisstudy.
Study Design
Total Participants: 30
Treatment Group(s): 3
Primary Treatment: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose
Phase:
Study Start date:
February 06, 2020
Estimated Completion Date:
September 14, 2023
Study Description
Connect with a study center
Xi'an International Medical Center Hospital
Xi'an, Shaanxi 710100
ChinaSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.